FindTrial
Sign In

naquotinib

DRUG3 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Epidermal Growth Factor Receptor (EGFR) MutationsEpidermal Growth Factor Receptor MutationsNon-Small-Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)Solid Tumors

Phase 1

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
CompletedNCT02113813
Astellas Pharma Global Development, Inc.Epidermal Growth Factor Receptor Mutations, Non-Small-Cell Lung Cancer (NSCLC)
Start: 2014-04-09End: 2019-02-11Updated: 2024-11-14
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors
WithdrawnNCT02674555
Astellas Pharma Global Development, Inc.Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors
Start: 2016-11-15End: 2016-11-15Updated: 2017-07-28
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
TerminatedNCT03082300
Astellas Pharma Global Development, Inc.Epidermal Growth Factor Receptor (EGFR) Mutations, Non-small Cell Lung Cancer (NSCLC)
Start: 2017-03-24End: 2017-06-19Updated: 2024-11-20

Related Papers

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
UNC Libraries2020-04-16
A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
2019-07-0124 citations
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
2018-08-0911 citations
<scp>ASP</scp>8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with <i><scp>EGFR</scp></i> mutation‐positive non‐small‐cell lung cancer
Cancer Science2018-05-2835 citations
A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
Clinical Cancer Research2017-09-2727 citations
Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.
Journal of Clinical Oncology2016-05-2029 citations
Abstract B188: Preclinical antitumor activity of ASP8273, a mutant-selective irreversible EGFR inhibitor in an AXL-overexpressing NSCLC model
Molecular Cancer Therapeutics2015-12-011 citations
Abstract 2586: ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models
Cancer Research2015-08-019 citations
Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.
Journal of Clinical Oncology2015-05-2015 citations